Top Tweets for #COMydAL
Outstanding talk by Professor @SKordasti in #IACH2025 #ComyDAL meeting in Paris on immune targeting in #MDSsm

Best team leading IACH dayS in paris #colym #comydal #mpncod @AnnaSureda5 @Dr_AmerZeidan @Mohty_EBMT and Arnon Nagler

CONGRESS | #IACH23 | #CoMyDAL @SridharChaganti, @uhbtrust discusses the role of CAR T-cell therapy in ALL and the indications for transplantation according to cytogenetics, MRD risk, relapsed disease, and post CAR T-cell therapy #allsm #leusm #medicalcongress

CONGRESS | #IACH23 | #CoMyDAL
Nicola Goekbuget, @goetheuni presents clinical data on the treatment of T-ALL using GMALL protocols highlighting the need for standardized classification systems and improved treatment options for R/R T-ALL #allsm #leusm

#IACH23 | #CoMyDAL Elias Jabbour,
@MDAndersonNews delivers an interesting talk on the management of Ph-positive ALL, highlighting whether we still need allo-SCT, high efficacy of ponatinib, & new therapies such as olverembatinib currently being explored in this setting #allsm

CONGRESS | #IACH23 | #CoMyDAL Robin Foà @SapienzaRoma gave a presentation on Ph-negative ALL highlighting the key role of MRD monitoring and immunotherapies such as blinatumomab on clinical outcomes
#allsm #leusm


@MSubklewe with a tour-de-force talk on new directions & challenges of immune therapies in #AMLsm & #MDSsm @TheIACH #COMyDAL


@KlausMetzelerMD giving a fantastic talk on resistance mechanics to novel therapies in @IACH #COMyDAL

CONGRESS | #IACH23 | #CoMyDAL
Naval Daver @Daver_Leukemia @LeukemiaMDA reviews firstline therapies for fit patients on behalf of Jessica Altman @jaltmanmd.
· Value of molecular MRD in getting data quickly, and potential to include NGS in regulatory endpoints
· Transplant decisions are dynamic
· Promising trial results of FLAG-Ida-Ven
· High interest in FLT3i including quizartinib, and exciting Aza-ven plus gilteritinib data
@TheIACH #IACH2023 #AMLsm

CONGRESS | #IACH23 | #CoMyDAL
Thomas Cluzeau @thomas_cluzeau @Univ_CotedAzur shares his thoughts on the most promising agents in development:
· IMGN632 plus Aza-Ven backbone
· Gilteritinib plus Aza-Ven backbone
· Magrolimab in TP53m AML
@TheIACH #IACH2023 #amlsm

CONGRESS | #IACH23 | #CoMyDAL
Marion Subklewe @subklewe @LMU_Muenchen describes current immunotherapy landscape in AML and challenges, including target antigen choice. She covers GO as the only currently approved option, antibody-based agents and the need for step-up dosing to mitigate CRS, bispecifics including pre-clinical models with Ven-Aza, and the future of CAR T and NK cells.
@TheIACH #IACH2023 #AMLsm

CONGRESS | #IACH23 | #CoMyDAL
Gail Roboz @WCMLeukemia @nyphospital asks whether adding more agents is better?
· Additive strategy for FLT3 inhibitors on top of baseline agents
· Triplets may not add everywhere, patient decision making needed
· Power triplets and suggestions for OS benefit with FLAG-Ida+Ven, ClIA+Ven
· Unable to do all the randomized studies needed for all patient subgroups and drug combinations
· Excitement over potential menin inhibitor triplets with low and intensive chemo
@TheIACH #IACH2023 #AMLsm

CONGRESS | #IACH23 | #CoMyDAL
Andrew Wei, @PeterMacCC, presents the challenges of treating R/R AML, highlighting 5yr survival still < 10%. He runs through current and potential future therapeutic options, querying what treatment might look like with all the new firstline agents?
@TheIACH #IACH2023 #AMLsm

Outstanding panel discussions on all aspects of #MDSsm in @TheIACH #COMyDAL meeting. What a true pleasure to co-chair the meeting with the one & only dr @Santin13Valeria & have such amazing faculty join us for very robust discussions & debates on how to move the field forward

CONGRESS | #IACH23 | #CoMyDAL
Raphael Itzykson @raphaelitzykson @HopSaintLouis talks describes the need for a clear definition of MDS/AML. He describes therapeutic strategies including the benefit seen with CPX-351 in patients with MDS-type mutations and the potential of HMA+Ven.
@TheIACH #IACH2023 #AMLsm #MDSsm

Last Seen Hashtags on Sotwe
blacksexvideos
Seen from France
columbiafreaks
Seen from Turkey
UTHMexperts
Seen from United States
ItsAlsoColorWars
Seen from United States
QOD
Seen from Germany
blacked
دختر
Seen from United Arab Emirates
tepexiprogresista
Seen from United States
سـكـــسً
Seen from Switzerland
sallingcontent
Seen from Switzerland
Most Popular Users

Elon Musk 
@elonmusk
241.8M followers

Barack Obama 
@barackobama
119M followers

Cristiano Ronaldo 
@cristiano
114.6M followers

Donald J. Trump 
@realdonaldtrump
111.9M followers

Narendra Modi 
@narendramodi
107.2M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.4M followers

Justin Bieber 
@justinbieber
91.8M followers

KATY PERRY 
@katyperry
90.1M followers

Taylor Swift 
@taylorswift13
84M followers

Lady Gaga 
@ladygaga
75.5M followers

Virat Kohli 
@imvkohli
73.5M followers

Kim Kardashian 
@kimkardashian
70.9M followers

YouTube 
@youtube
68.8M followers

Neymar Jr 
@neymarjr
66.5M followers

Bill Gates 
@billgates
65.3M followers

Selena Gomez 
@selenagomez
63.1M followers

The Ellen Show
@theellenshow
62.3M followers

CNN 
@cnn
61.8M followers

X 
@x
60.7M followers










































